What are the indications for digitalis (digoxin)?

Indications for Digitalis (Digoxin)

Digoxin is indicated for two primary conditions: (1) rate control in atrial fibrillation with heart failure, and (2) symptomatic heart failure with reduced ejection fraction (LVEF ≤40%) in patients who remain symptomatic despite optimal therapy with ACE inhibitors/ARBs, beta-blockers, and diuretics. 1

Primary Indications

1. Atrial Fibrillation with Heart Failure

• Use digoxin to slow rapid ventricular rate in patients with symptomatic heart failure and atrial fibrillation 2, 3, 2
• Target ventricular rate: <80 bpm at rest, <110-120 bpm during exercise 2
• In patients with AF and LVEF <40%, digoxin should be used for rate control in addition to, or prior to, a beta-blocker (Class I recommendation, Level C evidence) 2, 3
• Beta-blockers are preferred long-term for rate control, either alone or combined with digoxin, as they provide additional mortality benefits 2

2. Heart Failure with Reduced Ejection Fraction (Sinus Rhythm)

• Indicated for symptomatic HF patients with LVEF ≤40% in NYHA class II-IV who remain symptomatic despite treatment with ACE inhibitors/ARBs, beta-blockers, and diuretics 2, 3
• Improves ventricular function, patient well-being, and reduces hospitalizations for worsening heart failure by 28% 2, 4
• Does NOT reduce mortality - this is a critical distinction from other HF medications 2, 4
• Class IIa recommendation, Level B evidence for sinus rhythm 2, 3

Dosing Approach

Standard Dosing

• Start with 0.125-0.25 mg daily for most patients with normal renal function 5, 2
• Use 0.0625-0.125 mg daily in elderly patients (>70 years), those with renal impairment, or low lean body mass 2, 6
• No loading doses needed for chronic stable heart failure 5
• Target serum concentration: 0.5-1.0 ng/mL (lower than historically recommended) 2, 3

Important Dosing Nuances

The evidence shows that concentrations >1.0 ng/mL are associated with increased mortality without superior outcomes 6. This represents a significant shift from older therapeutic ranges of 0.8-2.0 ng/mL.

Absolute Contraindications

Do not use digoxin in patients with: 5, 2, 1

• Ventricular fibrillation
• Second- or third-degree AV block (without permanent pacemaker)
• Sick sinus syndrome
• Pre-excitation syndromes (Wolff-Parkinson-White)
• Known hypersensitivity to digoxin
• Hypertrophic obstructive cardiomyopathy (unless atrial fibrillation present)

Critical Safety Monitoring

Mandatory Monitoring

• Serial monitoring of serum potassium, magnesium, and renal function is mandatory 2, 3
• Hypokalemia and hypomagnesemia dramatically increase arrhythmia risk 2
• Check digoxin levels early in therapy, particularly in elderly and renally impaired patients 2, 3

Drug Interactions That Increase Digoxin Levels

Be cautious with concomitant use of: 3

• Amiodarone
• Verapamil, diltiazem
• Quinidine
• Spironolactone
• Certain antibiotics

Reduce digoxin dose by 50% when adding amiodarone 6

Common Pitfalls to Avoid

1. Do not use digoxin as primary therapy for acute decompensated heart failure - stabilize patients first with intravenous medications, then consider digoxin as part of long-term strategy 6

2. Do not use high doses (>0.25 mg daily) for rate control in atrial fibrillation - add beta-blockers or amiodarone instead for additional rate control 6, 7

3. Do not use in heart failure with preserved ejection fraction (HFpEF) - no benefit demonstrated 3, 2

4. Do not withdraw digoxin abruptly if patient is already taking it - continue while optimizing neurohormonal antagonists (ACE inhibitors, beta-blockers) 6

Signs of Toxicity

Watch for: 2, 3, 2

• Cardiac: Sinoatrial and AV block, atrial and ventricular arrhythmias
• Neurologic: Confusion
• Gastrointestinal: Nausea, anorexia
• Visual: Color vision disturbances (classically yellow-green halos)

For life-threatening ventricular arrhythmias from digoxin toxicity, use digoxin-specific Fab antibody fragments 2, 3

Clinical Context and Treatment Hierarchy

The guidelines consistently position digoxin as an adjunctive therapy, not first-line treatment. The algorithmic approach is:

1. First: Optimize diuretics, ACE inhibitors/ARBs, and beta-blockers
2. Second: Consider aldosterone antagonists in NYHA III-IV
3. Third: Add digoxin if symptoms persist despite above therapies

This hierarchy reflects that digoxin improves symptoms and reduces hospitalizations but does not reduce mortality, unlike the neurohormonal antagonists 2, 6, 4.